「2.5d」の検索結果
413件：6～10件目を表示
-
お知らせ | 千寿製薬株式会社
December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann
http://www.senju.co.jp/english/news/ -
Mytear ALPITATTO EXα | OTC Products, etc. | Products | SENJU Pharmaceutical
This medicine is recommended for people who have continuing allergy symptoms with inflammation. Category 2 OTC medicines Mytear® ALPITATTO EXα Works on unbearable eye itching due to pollens and other
http://www.senju.co.jp/english/products/apex.html -
Milestones in Our History | About Senju | SENJU Pharmaceutical
1947 Apri Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. July Injection Product for Neutropenia, "PANILTIN", sales launched 1949 Feb
https://www.senju.co.jp/english/about/history.html -
Mytear EYETECT ALPITATTO N | OTC Products, etc. | Products | SENJU Pharmaceutical
This medicine is recommended for people who have continuing allergy symptoms with inflammation. Category 2 OTC medicines Mytear® EYETECT® ALPITATTON Works on unpleasant eye itching due to pollens and
http://www.senju.co.jp/english/products/apn.html -
March 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307_0.pdf